cyc 202 has been researched along with vidarabine in 4 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (vidarabine) | Trials (vidarabine) | Recent Studies (post-2010) (vidarabine) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 4,976 | 974 | 1,525 |
| Protein | Taxonomy | cyc 202 (IC50) | vidarabine (IC50) |
|---|---|---|---|
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.062 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Błoński, JZ; Kiliańska, ZM; Robak, T; Wesierska-Gadek, J; Zolnierczyk, JD | 1 |
| Błoński, JZ; Góralski, P; Kiliańska, ZM; Komina, O; Piekarski, H; Robak, T; Rogalińska, M; Wesierska-Gadek, J; Zołnierczyk, JD | 1 |
| Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Komina, O; Robak, P; Smolewski, P; Węsierska-Gądek, J; Żołnierczyk, JD | 1 |
4 other study(ies) available for cyc 202 and vidarabine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Cell Survival; Cells, Cultured; Cladribine; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclophosphamide; Drug Synergism; Female; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Vidarabine | 2009 |
R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Survival; Cells, Cultured; Cladribine; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Cyclophosphamide; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Purines; Roscovitine; Vidarabine | 2010 |
Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purines; Roscovitine; Vidarabine | 2012 |